In the past week, AMLX stock has gone up by 9.81%, with a monthly gain of 31.08% and a quarterly surge of 59.02%. The volatility ratio for the week is 9.09%, and the volatility levels for the last 30 days are 6.96% for Amylyx Pharmaceuticals Inc The simple moving average for the last 20 days is 18.51% for AMLX stock, with a simple moving average of -55.39% for the last 200 days.
Is It Worth Investing in Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Right Now?
The 36-month beta value for AMLX is also noteworthy at -0.61. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AMLX is 41.15M, and at present, short sellers hold a 3.61% of that float. The average trading volume of AMLX on September 24, 2024 was 1.66M shares.
AMLX) stock’s latest price update
The stock price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) has plunged by -6.13 when compared to previous closing price of 3.10, but the company has seen a 9.81% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-16 that NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with Mizuho repeating the rating for AMLX by listing it as a “Neutral.” The predicted price for AMLX in the upcoming period, according to Mizuho is $4 based on the research report published on March 18, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $4, previously predicting the price at $37. The rating they have provided for AMLX stocks is “Neutral” according to the report published on March 11th, 2024.
Leerink Partners gave a rating of “Market Perform” to AMLX, setting the target price at $4 in the report published on March 11th of the current year.
AMLX Trading at 31.63% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.41% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 9.09%, as shares surge +30.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.72% upper at present.
During the last 5 trading sessions, AMLX rose by +9.81%, which changed the moving average for the period of 200-days by -80.44% in comparison to the 20-day moving average, which settled at $2.49. In addition, Amylyx Pharmaceuticals Inc saw -80.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from FRATES JAMES M, who purchase 40,000 shares at the price of $2.53 back on Sep 12 ’24. After this action, FRATES JAMES M now owns 233,464 shares of Amylyx Pharmaceuticals Inc, valued at $101,368 using the latest closing price.
Firestone Karen, the Director of Amylyx Pharmaceuticals Inc, purchase 50,000 shares at $2.13 during a trade that took place back on Sep 05 ’24, which means that Firestone Karen is holding 55,000 shares at $106,590 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -0.52 for the present operating margin
- 0.53 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at -0.56. The total capital return value is set at -0.59. Equity return is now at value -51.22, with -42.22 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.68. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -44.82.
Currently, EBITDA for the company is 39.89 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 0.42. The receivables turnover for the company is 71.29for trailing twelve months and the total asset turnover is 0.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.66.
Conclusion
In summary, Amylyx Pharmaceuticals Inc (AMLX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
